Reboud-Ravaux M - Search Results

1

Structure-based design of human immuno- and constitutive proteasomes inhibitors.

Richy N, Sarraf D, Maréchal X, Janmamode N, Le Guével R, Genin E, Reboud-Ravaux M, Vidal J. Richy N, et al. Among authors: reboud ravaux m. Eur J Med Chem. 2018 Feb 10;145:570-587. doi: 10.1016/j.ejmech.2018.01.013. Epub 2018 Jan 8. Eur J Med Chem. 2018. PMID: 29339252 Free article.

2

Linear TMC-95-based proteasome inhibitors.

Basse N, Piguel S, Papapostolou D, Ferrier-Berthelot A, Richy N, Pagano M, Sarthou P, Sobczak-Thépot J, Reboud-Ravaux M, Vidal J. Basse N, et al. J Med Chem. 2007 Jun 14;50(12):2842-50. doi: 10.1021/jm0701324. Epub 2007 May 19. J Med Chem. 2007. PMID: 17511440

3

Novel organic proteasome inhibitors identified by virtual and in vitro screening.

Basse N, Montes M, Maréchal X, Qin L, Bouvier-Durand M, Genin E, Vidal J, Villoutreix BO, Reboud-Ravaux M. Basse N, et al. J Med Chem. 2010 Jan 14;53(1):509-13. doi: 10.1021/jm9011092. J Med Chem. 2010. PMID: 19919035

4

Noncovalent inhibition of 20S proteasome by pegylated dimerized inhibitors.

Maréchal X, Pujol A, Richy N, Genin E, Basse N, Reboud-Ravaux M, Vidal J. Maréchal X, et al. Eur J Med Chem. 2012 Jun;52:322-7. doi: 10.1016/j.ejmech.2012.02.052. Epub 2012 Mar 5. Eur J Med Chem. 2012. PMID: 22440858

5

Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome.

Desvergne A, Genin E, Maréchal X, Gallastegui N, Dufau L, Richy N, Groll M, Vidal J, Reboud-Ravaux M. Desvergne A, et al. J Med Chem. 2013 Apr 25;56(8):3367-78. doi: 10.1021/jm4002007. Epub 2013 Apr 17. J Med Chem. 2013. PMID: 23540790

6

Noncovalent fluorescent probes of human immuno- and constitutive proteasomes.

Desvergne A, Cheng Y, Grosay-Gaudrel S, Maréchal X, Reboud-Ravaux M, Genin E, Vidal J. Desvergne A, et al. J Med Chem. 2014 Nov 13;57(21):9211-7. doi: 10.1021/jm5011429. Epub 2014 Nov 4. J Med Chem. 2014. PMID: 25333324

7

Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.

Villoutreix BO, Khatib AM, Cheng Y, Miteva MA, Maréchal X, Vidal J, Reboud-Ravaux M. Villoutreix BO, et al. Oncotarget. 2017 Feb 7;8(6):10437-10449. doi: 10.18632/oncotarget.14428. Oncotarget. 2017. PMID: 28060729 Free PMC article.

8

Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.

Genin E, Reboud-Ravaux M, Vidal J. Genin E, et al. Curr Top Med Chem. 2010;10(3):232-56. doi: 10.2174/156802610790725515. Curr Top Med Chem. 2010. PMID: 20166955 Free article. Review.

9

1,2,4-Oxadiazoles identified by virtual screening and their non-covalent inhibition of the human 20S proteasome.

Maréchal X, Genin E, Qin L, Sperandio O, Montes M, Basse N, Richy N, Miteva MA, Reboud-Ravaux M, Vidal J, Villoutreix BO. Maréchal X, et al. Curr Med Chem. 2013;20(18):2351-62. doi: 10.2174/0929867311320180006. Curr Med Chem. 2013. PMID: 23531222

10

Novel fluorinated pseudopeptides as proteasome inhibitors.

Formicola L, Maréchal X, Basse N, Bouvier-Durand M, Bonnet-Delpon D, Milcent T, Reboud-Ravaux M, Ongeri S. Formicola L, et al. Bioorg Med Chem Lett. 2009 Jan 1;19(1):83-6. doi: 10.1016/j.bmcl.2008.11.012. Epub 2008 Nov 7. Bioorg Med Chem Lett. 2009. PMID: 19041239

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

86 results

Search Page